New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
07:02 EDTZSPHZS Pharma initiated with an Outperform at William Blair
William Blair believes management of hyperkalemia has the potential to become a significant market. The firm started shares of ZS Pharma with an Outperform rating and $75 price target.
News For ZSPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
08:27 EDTZSPHZS Pharma price target raised to $54 from $45 at BMO Capital
BMO Capital raised its price target on ZS Pharma as the firm thinks the market is appropriately upwardly adjusting its expectations for the potential of the company lead drug candidate, ZS-9, after positive data on the drug was released. The firm keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use